ロード中...
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease
Introduction: Agalsidase alfa and agalsidase beta, recombinant enzyme preparations for treatment of Fabry disease (FD), have different approved dosing schedules: 0.2 mg/kg and 1.0 mg/kg every other week (EOW), respectively. Methods: This open-label, multicenter, exploratory phase 4 study evaluated p...
保存先:
| 出版年: | JIMD Rep |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5059194/ https://ncbi.nlm.nih.gov/pubmed/26303609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/8904_2015_483 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|